JPRN-jRCT2080223322
Unknown
未知
An Expanded Access Program for Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma in Japan
Conditionsrelapsed or refractory multiple myeloma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- relapsed or refractory multiple myeloma
- Sponsor
- Bristol-Myers Squibb K.K.
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Men and women 20 years and older
- •Active, relapsed or refractory multiple myeloma by International Myeloma Working Group (IMWG) criteria as assessed by the treating physician and have received at least 1 prior line of multiple myeloma therapy.
- •Progression from a most recent line of therapy
- •Prior lenalidomide exposure is permitted only if they fulfill all of the following:
- •a.Were not refractory to prior lenalidomide, defined as no progression while receiving lenalidomide (induction dose) or within 60 days of last dose of lenalidomide. Patients progressing on lenalidomide maintenance dose are eligible for enrollment.
- •b.Patient did not discontinue lenalidomide due to a Grade over 3 related AE.
Exclusion Criteria
- •All Adverse Events of any prior chemotherapy, surgery, or radiotherapy not resolved to NCI CTCAE (v. 3\.0\) Grade under 2
- •Significant cardiac disease as determined by the treating physician including cardiac amyloidosis
- •Known HIV infection or active hepatitis A, B, or C
- •Any medical conditions that, in the attending physician's opinion, would impose excessive risk to the patient.
Outcomes
Primary Outcomes
Not specified
Similar Trials
No Longer Available
Not Applicable
Early Patient Access Treatment Use Protocol CA204-220Multiple MyelomaNCT02856438Bristol-Myers Squibb
No Longer Available
Not Applicable
Expanded Access Treatment Protocol CA204-143Multiple MyelomaNCT02368301Bristol-Myers Squibb
Active, not recruiting
Phase 1
Expanded access program for mepolizumab in subjects with HESSubjects with life-threatening HESMedDRA version: 20.0Level: PTClassification code 10048643Term: Hypereosinophilic syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2007-000838-39-GBGlaxoSmithKline Research & Development Ltd200
Active, not recruiting
Phase 1
Expanded access program for mepolizumab in subjects with HES.Subjects with life-threatening HESMedDRA version: 20.0Level: PTClassification code 10048643Term: Hypereosinophilic syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2007-000838-39-ESGlaxoSmithKline, S.A.200
Active, not recruiting
Phase 1
Expanded access program for mepolizumab in subjects with hypereosinophilic syndrome.Hypereosinophilic SyndromeTherapeutic area: Not possible to specifyTherapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]CTIS2024-515247-28-00Glaxosmithkline Research & Development Limited15